These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1183 related articles for article (PubMed ID: 21725655)

  • 21. Comparative topoisomerase IIa and ki 67 protein expression in papillary thyroid carcinoma based on tissue microarrays and image analysis.
    Manaios L; Tsiambas E; Alevizaki M; Karameris A; Alexopoulou D; Lambropoulou S; Moreas H; Kravvaritis C; Fotiades PP; Goula K; Patsouris E; Athanassiou AE; Koutras D; Katsilambros N
    J BUON; 2008; 13(4):537-41. PubMed ID: 19145676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
    J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of Topoisomerase II in female breast cancer.
    Koren R; Rath-Wolfson L; Ram E; Itzhac OB; Schachter B; Klein B; Gal R; Dreznik Z
    Oncol Rep; 2004 Oct; 12(4):915-9. PubMed ID: 15375522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer.
    O'Connor JK; Hazard LJ; Avent JM; Lee RJ; Fischbach J; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1411-5. PubMed ID: 16750309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
    Gómez HL; Pinto JA; Olivera M; Vidaurre T; Doimi FD; Vigil CE; Velarde RG; Abugattas JE; Alarcón E; Vallejos CS
    Breast; 2011 Feb; 20(1):39-45. PubMed ID: 20705464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
    Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
    Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations.
    Niemiec J; Adamczyk A; Małecki K; Ambicka A; Ryś J
    Clin Breast Cancer; 2013 Apr; 13(2):119-28. PubMed ID: 23375518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
    Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
    Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
    O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI
    Breast Cancer Res Treat; 2011 Jul; 128(2):401-9. PubMed ID: 21519837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
    Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.